Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

November 15, 2018

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

News Conference News VIVA 2018

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

November 13, 2018

Now You See Them, Now You Don’t: Bioresorbable Devices Target Large-Bore Closures and PE Prevention

News Conference News VIVA 2018

Now You See Them, Now You Don’t: Bioresorbable Devices Target Large-Bore Closures and PE Prevention

November 09, 2018

LUTONIX BTK Trial

Presentation VIVA 2018

LUTONIX BTK Trial

Presenter: Jihad Mustapha

November 09, 2018

TOBA II 12-Month Data

Presentation VIVA 2018

TOBA II 12-Month Data

Presenter: William Gray

November 09, 2018

1-Year Outcomes for Eluvia in Long Lesions

Presentation VIVA 2018

1-Year Outcomes for Eluvia in Long Lesions

Presenter: William A. Gray

November 09, 2018

Attacking DVT With Drug-Device Combo Does Not Reduce Postthrombotic Syndrome

News Conference News VIVA 2018

VERNACULAR: A Novel Venous Stent Shows Promise for Treatment of Iliofemoral Occlusive Disease

November 08, 2018

LUTONIX BTK: Hope for Challenging Patients at High Risk for Amputation

News Conference News VIVA 2018

LUTONIX BTK: Hope for Challenging Patients at High Risk for Amputation

November 07, 2018

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

News Conference News VIVA 2018

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

November 06, 2018

Conference VIVA 2018

VIVA 2018

Las Vegas, NV

November 05, 2018

November 08, 2018

Video

» Conference Wrap-Up

Conference Wrap Up: VIVA 2018

November 16, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.